ArticleNPJ precision oncology2026
Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric study.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Progression-Free Survival 2 as a Potential Surrogate for Overall Survival in Glioblastoma: Insights From a Spanish Multicentric Cohort.Cancer medicine · 2026Observational
- Artificial Intelligence in Transcriptomics: From Human-in-the-Loop to Agentic AI.Journal of personalized medicine · 2026Review
- Clinical trial design for primary brain tumors: a problem-based framework for neuro-oncology practice.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment options for patients with gliomas remain limited, and prognosis is generally poor. While next-generation sequencing (NGS) is increasingly used to stratify glioma patients and guide therapy, its implementation in routine clinical practice remains variable. We conducted a multicenter retrospective study across seven Spanish hospitals to evaluate the clinical utility of NGS in glioma management, focusing on its impact on diagnosis and treatment selection based on the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT). A total of 541 glioma patients diagnosed between 2018 and 2022 were included; 76% had glioblastomas and 24% other glioma subtypes. Among glioblastoma patients, 9% harbored ESCAT tier 1/2 alterations and 74% tier 3/4. Molecularly matched therapy was administered in 10.2% of glioblastoma cases. Objective responses were observed in 17.6% of glioblastoma and 33% of non-glioblastoma patients with ESCAT tier 1/2 alterations. Patients with tier 1/2 alterations experienced significantly longer progression-free survival compared to those with tier 3/4. These findings support genomic profiling of gliomas in research centers to expand therapeutic options in molecularly guided clinical trials.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.